Dr Filippo Bosco, Dr Robert Burger, Dr Marco Donolato
Innovation & Business Idea
The world is facing enormous challenges from the spread of infectious diseases. As recently featured in the global press, this burden is estimated to affect 1 billion people worldwide, killing 1.2 million every year. BluSense Diagnostics has developed an innovative blood testing technology that could transform the landscape of infectious disease diagnostics, in particular for Dengue fever. WHO estimates that the Dengue fatality rate could be 20 times lower if better Point-of-Care (POC) technology for early diagnostics was available.
Based on our proprietary opto-magnetic nanoparticle technology for highly sensitive and low-cost detection of biomarkers, we are developing a POC device capable to 1) quickly assess the nature and severity of infections, 2) facilitate diagnostics and outbreak monitoring of Dengue and other infectious diseases, and 3) get results in minutes from only a droplet of blood.
The largest potential markets are in South East Asia (SEA) and South America (SA), where Dengue and other mosquito-borne diseases are endemic. In SEA, Malaysia is an ideal entry market for several reasons: 1) Dengue is a major public concern, 2) comparatively favorable and transparent business environment, 3) it is a financial hub for SEA and a perfect starting point for expanding into other markets in the region. We work closely with a network of local collaborators. Promising entry markets in SA are Peru and Brazil, whereas market access and regulatory approval in Peru appears to be easier. Main customers will be GPs, health care centers and NGOs.
In order to effectively assess the severity of a Dengue infection several parameters have to be measured: the virus antigen NS1, and two specific human antibodies IgG and IgM.
Currently there is no device in the market which can measure all these parameters. Some devices can measure only NS1 or IgG/IgM. A few companies offer different devices to measure NS1 and IgG/IgM. However, solutions are either based on lateral flow strips (only quantitative, high risk of human error) or require expensive lab equipment and highly trained operators (ELISA). There is currently no user friendly quantitative POC solution in the market.
Intellectual Property Status
Two patent applications have been filed for the detection technology. Both received purely positive opinions from the EPO and national applications in relevant markets are currently being filed.
IP is owned by the Technical University of Denmark, however, BluSense has an exclusive license with very favorable terms.
Development Status & Future Steps
The reader device is currently being finalized, with the final version scheduled for Summer 2016. Successful detection of various biomarkers (CRP, HbA1c, Dengue NS1) has been demonstrated and BluSense aims to finalize NS1 and IgG/IgM assays for Dengue diagnostics by the end of 2016. Development of the assay cartridge and setup of pilot production line is scheduled for Q4 2016.
We envision an exit within 2-3 year from closing of round B via trade sale or IPO.
Leif Helth Jensen (Chairman) has been CEO and board member of more than 20 pharma and medtech companies worldwide.
Dr Donolato developed the core technology during the course of his PhD work. He is co-inventor of 3 patents, and main author of more than 25 high impact scientific papers.
Dr Bosco has undergone an intensive entrepreneurship training, participating in prestigious courses in US, Europe and China.
Dr Burger has been working for more than 8 years on developing microfluidics for POC diagnostics, in academia as well as in industry.
BluSense is seeking a B round of € 4 M, which will be used to bring the product to market.
Commercial Partner, Funding, Collaboration